Showing 631-640 of 1321 results for "".
- Castle's DecisionDx-SCC Provides Clarity in Assessing Risk SCC Spread in Challenging Staging Situationshttps://practicaldermatology.com/news/castles-decisiondx-scc-provides-clarity-in-assessing-risk-scc-spread-in-challenging-staging-situations/2461436/Castle Biosciences, Inc.’s DecisionDx-SCC test provides objective, independent and significant risk-stratification for cutaneous squamous cell carcinoma (cSCC) tumors with uncertainty in differentiation status. The data were shared in an oral presentation given at the Americ
- DermTech, Sonora Quest Laboratories Join Forces Expand Access to Melanoma Detection Test in Arizonahttps://practicaldermatology.com/news/dermtech-sonora-quest-laboratories-join-forces-expand-access-to-melanoma-detection-test-in-arizona/2461434/Sonora Quest is the exclusive laboratory offering the DermTech Melanoma Test for all of Arizona. The DermTech Melanoma Test uses a non-invasive Smart Sticker to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma. I
- Reistone Biopharma's Oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for ADhttps://practicaldermatology.com/news/reistone-biopharmas-oral-ivarmacitinib-meets-primary-endpoint-in-phase-iii-study-for-ad/2461431/Reistone Biopharma’s once daily Ivarmacitinib as monotherapy relieves in improving skin inflammation and itchiness n adults and adolescents with moderate-to-severe, according to a results from thePhase III QUARTZ3 study. The study evaluated the efficacy and safety of once dai
- Supergoop! Founder & CEO Named Ernst & Young LLP’s Entrepreneurs of the Year for 2022https://practicaldermatology.com/news/supergoop-founder-ceo-named-ernst-young-llps-entrepreneurs-of-the-year-for-2022/2461430/Holly Thaggard and Amanda Baldwin of Supergoop! are Ernst & Young LLP’s Entrepreneurs of the Year for 2022. The Entrepreneur of the Year program honors and elevates entrepreneurs who think big and act boldly to change our world for nearly four decades.
- ACR Study: Belimumab Improves CLE Toohttps://practicaldermatology.com/news/acr-study-belimumab-improves-cle/2461423/The B-cell inhibitor belimumab significantly improved cutaneous lupus erythematosus (CLE) whether or not patients also had systemic lupus erythematosus (SLE), according to research presented at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, Beli
- Meet Crown’s ProGen PRP Eclipsehttps://practicaldermatology.com/news/meet-crowns-progen-prp-eclipse/2461417/Crown Aesthetics completed the rebranding of ProGen PRP Advantage, now renamed ProGen PRP Eclipse. ProGen PRP Eclipse is a one-spin system that features 15 mL and 30 mL tubes, yielding 7-15 mL of Platelet Rich Plasma. "Crown's commitment to best-in-class service
- Cutera's AviClear Now Broadly Available to US Physicians and Practitionershttps://practicaldermatology.com/news/cuteras-aviclear-now-broadly-available-to-us-physicians-and-practitioners/2461416/Cutera, Inc.’s AviClear is now broadly available to physicians and practitioners treating patients throughout North America. AviClear is the first and only energy device to be both U.S. Food and Drug Administration cleared and Health Canada approved for
- Hydrafacial and Glytone Team Up to Launch New Boosterhttps://practicaldermatology.com/news/hydrafacial-and-glytone-team-up-to-launch-new-booster/2461414/The Beauty Health Company’s Hydrafacial is rolling out a new exfoliating booster co-created with Glytone. The Glytone AHA Resurfacing Cellular Booster leverages a unique combination of three alpha hydroxy acids (AHAs) that may help improve the appearance of skin surface and textur
- It's Time to Celebrate Allergan Aesthetics' Fourth Annual BOTOX Cosmetic Dayhttps://practicaldermatology.com/news/its-time-to-celebrate-allergan-aesthetics-fourth-annual-botox-cosmetic-day/2461413/Allergan Aesthetics is inviting people across the country to take a "Moment for You" on Wednesday, November 16 and celebrate the biggest event of the year for Botox Cosmetic. For this year's celebration, BOTOX® Cosmetic is sharing two exclusive offers availab
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod